Better Therapeutics (NASDAQ:BTTX – Get Rating) is one of 33 publicly-traded companies in the “Health services” industry, but how does it contrast to its rivals? We will compare Better Therapeutics to similar companies based on the strength of its valuation, profitability, institutional ownership, analyst recommendations, earnings, risk and dividends.
Volatility and Risk
Better Therapeutics has a beta of 1.44, suggesting that its share price is 44% more volatile than the S&P 500. Comparatively, Better Therapeutics’ rivals have a beta of 1.48, suggesting that their average share price is 48% more volatile than the S&P 500.
Insider & Institutional Ownership
7.5% of Better Therapeutics shares are owned by institutional investors. Comparatively, 48.6% of shares of all “Health services” companies are owned by institutional investors. 59.4% of Better Therapeutics shares are owned by company insiders. Comparatively, 21.6% of shares of all “Health services” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
|Net Margins||Return on Equity||Return on Assets|
|Better Therapeutics Competitors||-325.87%||-481.74%||-38.64%|
Valuation & Earnings
This table compares Better Therapeutics and its rivals revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Better Therapeutics||$10,000.00||-$40.33 million||-0.70|
|Better Therapeutics Competitors||$1.36 billion||-$98.47 million||29.04|
Better Therapeutics’ rivals have higher revenue, but lower earnings than Better Therapeutics. Better Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
This is a summary of recent ratings and recommmendations for Better Therapeutics and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Better Therapeutics Competitors||7||129||274||0||2.65|
Better Therapeutics presently has a consensus target price of $14.00, indicating a potential upside of 892.91%. As a group, “Health services” companies have a potential upside of 111.55%. Given Better Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Better Therapeutics is more favorable than its rivals.
Better Therapeutics beats its rivals on 7 of the 12 factors compared.
Better Therapeutics Company Profile
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
Receive News & Ratings for Better Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Better Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.